Ezetimibe
- Generic Name
- Ezetimibe
- Brand Names
- Ezetrol, Lypqozet, Nexlizet, Roszet, Vytorin, Zetia
- Drug Type
- Small Molecule
- Chemical Formula
- C24H21F2NO3
- CAS Number
- 163222-33-1
- Unique Ingredient Identifier
- EOR26LQQ24
- Background
Ezetimibe is a lipid-lowering compound that inhibits intestinal cholesterol and phytosterol absorption. The discovery and research of this drug began in the early 1990s, after the intravenous administration of radiolabelled ezetimibe in rats revealed that it was being localized within enterocytes of the intestinal villi - this prompted studies investigating ...
- Indication
Ezetimibe is indicated to reduce elevated total-C, LDL-C, Apo B, and non-HDL-C in patients with primary hyperlipidemia, alone or in combination with an HMG-CoA reductase inhibitor (statin). It is also indicated to reduce elevated total-C, LDL-C, Apo B, and non-HDL-C in patients with mixed hyperlipidemia in combination with fenofibrate, and to reduce elevated...
- Associated Conditions
- Elevated Blood Lipids, Elevated sitosterol and campesterol
- Associated Therapies
- -
Silent Cerebrovascular Lesion and Cognitive Decline Prevention by Cholesterol Lowering in Elderly AF Patients
- Conditions
- First Posted Date
- 2007-03-20
- Last Posted Date
- 2007-03-20
- Lead Sponsor
- Radboud University Medical Center
- Target Recruit Count
- 35
- Registration Number
- NCT00449410
- Locations
- 🇳🇱
Gheorghe AM Pop, Nijmegen, Netherlands
A Study Evaluating the Safety and Efficacy of AVE5530 (4 Weeks) in Patients With Mild to Moderate Hypercholesterolemia
- Conditions
- Interventions
- First Posted Date
- 2007-02-26
- Last Posted Date
- 2008-12-16
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 206
- Registration Number
- NCT00440154
- Locations
- 🇹🇷
Sanofi-Aventis Administrative Office, Istanbul, Turkey
The Safety & Efficacy of Combination BMS-201038 (AEGR-733) & Ezetimibe vs. Monotherapy in Moderate Hypercholesterolemia
- Conditions
- First Posted Date
- 2006-11-29
- Last Posted Date
- 2014-03-04
- Lead Sponsor
- Aegerion Pharmaceuticals, Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT00405067
- Locations
- 🇺🇸
Pharmanet, Inc, Princeton, New Jersey, United States
Comparative Study of the Effect of Ezetimibe Versus Extended-Release Niacin on Atherosclerosis
- First Posted Date
- 2006-11-09
- Last Posted Date
- 2009-06-17
- Lead Sponsor
- Walter Reed Army Medical Center
- Target Recruit Count
- 400
- Registration Number
- NCT00397657
- Locations
- 🇺🇸
Walter Reed Army Medical Center, Washington, District of Columbia, United States
🇺🇸Washington Adventist Hospital, Takoma Park, Maryland, United States
Effect of Ezetimibe on Flow-mediated Brachial Artery Reactivity in Healthy Subjects
- First Posted Date
- 2006-09-14
- Last Posted Date
- 2020-02-12
- Lead Sponsor
- University of California, San Diego
- Target Recruit Count
- 28
- Registration Number
- NCT00376246
Pharmacokinetic Drug Interactions of AEGR-733 on Lipid-lowering Agents
- Conditions
- First Posted Date
- 2006-08-02
- Last Posted Date
- 2018-02-23
- Lead Sponsor
- Aegerion Pharmaceuticals, Inc.
- Target Recruit Count
- 125
- Registration Number
- NCT00359281
- Locations
- 🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States
Adding Ezetimibe Tablet to Ongoing Treatment With Atorvastatin in Subjects With High Cholesterol and Multiple Coronary Heart Disease Risk Factors (Study P04060)(COMPLETED)
- Conditions
- Interventions
- First Posted Date
- 2006-04-27
- Last Posted Date
- 2022-02-09
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 22
- Registration Number
- NCT00319449
LDL Receptor Under Ezetimibe and Simvastatin
- Conditions
- First Posted Date
- 2006-04-25
- Last Posted Date
- 2014-12-03
- Lead Sponsor
- University of Cologne
- Target Recruit Count
- 60
- Registration Number
- NCT00317993
- Locations
- 🇩🇪
Medizinische Klinik II und Poliklinik für Innere Medizin, Cologne, Germany
To Evaluate Ezetimibe Plus Atorvastatin Versus Atorvastatin in Patients With High Cholesterol Not Controlled on Atorvastatin 40 mg (0653-090)
- First Posted Date
- 2006-01-13
- Last Posted Date
- 2024-05-14
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 579
- Registration Number
- NCT00276484
Efficacy of Lapaquistat Acetate Alone and With Ezetimibe in Subjects With Primary Dyslipidemia.
- Conditions
- Interventions
- First Posted Date
- 2005-12-22
- Last Posted Date
- 2012-05-24
- Lead Sponsor
- Takeda
- Target Recruit Count
- 1267
- Registration Number
- NCT00268697
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.